Condition
Levodopa Induced Dyskinesia (LID)
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results75% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (3)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02153632Phase 3Terminated
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
NCT02202551Phase 3Completed
Open-Label Safety Study of ADS-5102 in PD Patients With LID
NCT02136914Phase 3Completed
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
NCT02439203Phase 2Completed
Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia
Showing all 4 trials